Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity

Abstract Background New biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) all showed greater clinical benefits in the treatment of patients with rheumatoid arthritis (RA) with high disease activity, but imposed higher cost...

Full description

Bibliographic Details
Main Authors: Juthamas Prawjaeng, Pattara Leelahavarong, Nuttakarn Budtarad, Songyot Pilasant, Chonticha Chanjam, Wanruchada Katchamart, Pongthorn Narongroeknawin, Tasanee Kitumnuaypong
Format: Article
Language:English
Published: BMC 2023-05-01
Series:BMC Health Services Research
Subjects:
Economic evaluation
Cost-utility analysis
Disease-modifying antirheumatic drugs
Biologic DMARDs
Targeted synthetic DMARDs
Biosimilar DMARDs
Online Access:https://doi.org/10.1186/s12913-023-09595-1

Internet

https://doi.org/10.1186/s12913-023-09595-1

Similar Items